Allarity Therapeutics, Inc., a biopharmaceutical company, has filed a Registration Statement on Form S-8 with the Securities and Exchange Commission (SEC) on March 25, 2024. This filing pertains to the amendment and restatement of the company's 2021 Equity Incentive Plan, which was approved by the Board of Directors on March 7, 2024. The plan has been amended to increase the number of shares of common stock that may be issued by an additional 1,000,000 shares. The Registration Statement registers 295,751 shares that were added on January 1, 2024, due to an automatic annual increase provision, as well as the newly added 1,000,000 shares. The company, headquartered in Boston, Massachusetts, is categorized as a non-accelerated filer, a smaller reporting company, and an emerging growth company under SEC regulations. The documents required for the Section 10(a) prospectus are not filed with the SEC but will be provided to participants as specified by Rule 428(b)(1) under the Securities Act of 1933.

Allarity Therapeutics, Inc., a biopharmaceutical company, has filed a Registration Statement on Form S-8 with the Securities and Exchange Commission (SEC) on March 25, 2024. This filing pertains to the amendment and restatement of the company's 2021 Equity Incentive Plan, which was approved by the Board of Directors on March 7, 2024. The plan has been amended to increase the number of shares of common stock that may be issued by an additional 1,000,000 shares. The Registration Statement registers 295,751 shares that were added on January 1, 2024, due to an automatic annual increase provision, as well as the newly added 1,000,000 shares. The company, headquartered in Boston, Massachusetts, is categorized as a non-accelerated filer, a smaller reporting company, and an emerging growth company under SEC regulations. The documents required for the Section 10(a) prospectus are not filed with the SEC but will be provided to participants as specified by Rule 428(b)(1) under the Securities Act of 1933.